One development caught our attention.
Zacks recently upgraded Novavax (NASDAQ: NVAX) from a Hold to a Strong Buy.
That’s a meaningful change.
In this Deep Dive, we examine what may have driven the upgrade, why Cantor Fitzgerald remains constructive, and whether Novavax’s transition to a royalty- and partnership-driven business model is beginning to gain traction.
The market still sees uncertainty.
We’re watching the underlying business.
Topics Covered
Why Zacks upgraded NVAX from Hold to Strong Buy
Earnings surprises and analyst estimate revisions
Cantor Fitzgerald’s bullish outlook
Matrix-M licensing opportunity
Sanofi partnership and royalty potential
Novavax financial transformation
Risks and what investors should watch going forward
Disclosure: I am long shares of NVAX. Quiet Bull is for informational and educational purposes only and should not be considered personalized investment advice or a recommendation to buy or sell any security. Investing involves risk, including the possible loss of principal.
